A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients
ConditionHypertension
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age19+
SponsorHanmi Pharmaceutical Company Limited
About this trial
A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension
Eligibility criteria
Qualifiers
Subjects whose clinic blood pressure measured in visit 1 corresponds to the following conditions
sitSBP<180 mmHg and sitDBP<110mg for patients receiving any BP-lowering drug within 1 month prior to Visit 1
140mmHG≤sitSBP<180mmHg and 60mmHg≤sitDBP<110mmHg
Subjects whose clinic and ambulatory blood pressure measured in visit 2 corresponds to the following conditions
Disqualifiers
Difference between arms greater than 20 mmHg for mean sitSBP or 10mmHg for mean sitDBP at Visit 1
Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1
Orthostatic hypotension with symptoms within 3 months prior to visit 1
Secondary hypertension patient or suspected to be
Trial design
Treatments tested in this trial
- HGP2102-1
- HGP2102-2
- RLD2209-1
- RLD2209-2
Treatment groups
324 Participants
are divided into 3 treatment groupsLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Sevrance hosptalRecruiting03722, Seodaemun-gu, SeoulSouth Korea
Sponsors and collaborators
Source ClinicalTrials.gov